Journal of Clinical Oncology, Vol 16, 338-347, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Current perspectives on radiation-induced breast cancer

PE Goss and S Sierra
The Toronto Hospital-General Division, Canada. pegoss@interlog.com

PURPOSE: An approach to screening and detection of radiation-induced breast cancer is offered. Primary and secondary prevention strategies are suggested and the need for prospective clinical trials is emphasized. METHODS: Data are reviewed from published evidence of radiation-induced breast cancer secondary to atomic bomb radiation, occupational, and therapeutic exposure, especially that incurred during successful treatment of Hodgkin's disease (HD). Preclinical studies are reviewed to explore potential risk factors. RESULTS: Risk factors evident in the link between radiation and breast cancer include the differentiation of breast tissue as mediated by age and hormonal influence. Evidence is presented exploring the link between genetics and breast cancer, including specific genes such as the BRCA1 and BRCA2 genes, the p53 gene, the ataxia telangiectasia (AT) gene, and other nonspecific alterations in DNA repair proficiency. In light of these findings, steps toward primary prevention are discussed, including avoiding radiation exposure, genetic screening, and manipulation of the hormonal milieu. Secondary prevention may also be possible with the use of tamoxifen, low-fat diets, and/or the consumption of flaxseed. CONCLUSION: Our current recommendations for patients irradiated before 30 years of age for Hodgkin's disease include breast self-examination (BSE) monthly, yearly mammography 8 years postirradiation, and regular physical examinations every 6 months. Given the clear link between radiation exposure and breast cancer, we strongly recommend a prospective trial randomize patients to different levels of intensity of surveillance to monitor the efficacy of such screening efforts.

This article has been cited by other articles:

				M. J. Hooning, B. M.P. Aleman, M. Hauptmann, M. H.A. Baaijens, J. G.M. Klijn, R. Noyon, M. Stovall, and F. E. van Leeuwen Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer J. Clin. Oncol., December 1, 2008; 26(34): 5561 - 5568. [Abstract] [Full Text] [PDF]

				A. Bradbury and O. I. Olopade The Case for Individualized Screening Recommendations for Breast Cancer J. Clin. Oncol., July 20, 2006; 24(21): 3328 - 3330. [Full Text] [PDF]

				W. Landier, S. Bhatia, D. A. Eshelman, K. J. Forte, T. Sweeney, A. L. Hester, J. Darling, F. D. Armstrong, J. Blatt, L. S. Constine, et al. Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline J. Clin. Oncol., December 15, 2004; 22(24): 4979 - 4990. [Abstract] [Full Text] [PDF]

				E. Warner, D. B. Plewes, K. A. Hill, P. A. Causer, J. T. Zubovits, R. A. Jong, M. R. Cutrara, G. DeBoer, M. J. Yaffe, S. J. Messner, et al. Surveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination JAMA, September 15, 2004; 292(11): 1317 - 1325. [Abstract] [Full Text] [PDF]

				K. Behringer, A. Josting, P. Schiller, H. T. Eich, H. Bredenfeld, V. Diehl, and A. Engert Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group Ann. Onc., July 1, 2004; 15(7): 1079 - 1085. [Abstract] [Full Text] [PDF]

				S. Bhatia, Y. Yasui, L. L. Robison, J. M. Birch, M. K. Bogue, L. Diller, C. DeLaat, F. Fossati-Bellani, E. Morgan, O. Oberlin, et al. High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin's Disease: Report From the Late Effects Study Group J. Clin. Oncol., December 1, 2003; 21(23): 4386 - 4394. [Abstract] [Full Text] [PDF]

				B. M.P. Aleman, A. W. van den Belt-Dusebout, W. J. Klokman, M. B. van't Veer, H. Bartelink, and F. E. van Leeuwen Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin's Disease J. Clin. Oncol., September 15, 2003; 21(18): 3431 - 3439. [Abstract] [Full Text] [PDF]

				F. E. van Leeuwen, W. J. Klokman, M. Stovall, E. C. Dahler, M. B. van't Veer, E. M. Noordijk, M. A. Crommelin, B. M. P. Aleman, A. Broeks, M. Gospodarowicz, et al. Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease J Natl Cancer Inst, July 2, 2003; 95(13): 971 - 980. [Abstract] [Full Text] [PDF]

				A. Foss Abrahamsen, A. Andersen, O. Nome, A. B. Jacobsen, H. Holte, J. Foss Abrahamsen, and S. Kvaloy Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time Ann. Onc., November 1, 2002; 13(11): 1786 - 1791. [Abstract] [Full Text] [PDF]

				T. Dork, R. Bendix, M. Bremer, D. Rades, K. Klopper, M. Nicke, B. Skawran, A. Hector, P. Yamini, D. Steinmann, et al. Spectrum of ATM Gene Mutations in a Hospital-based Series of Unselected Breast Cancer Patients Cancer Res., October 1, 2001; 61(20): 7608 - 7615. [Abstract] [Full Text] [PDF]

				P. E. Blackshear Genetically Engineered Rodent Models of Mammary Gland Carcinogenesis: An Overview Toxicol Pathol, January 1, 2001; 29(1): 105 - 116. [Abstract] [PDF]

				A.-M. Martin and B. L. Weber Genetic and Hormonal Risk Factors in Breast Cancer J Natl Cancer Inst, July 19, 2000; 92(14): 1126 - 1135. [Abstract] [Full Text] [PDF]

				C. Metayer, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, T. Joensuu, F. E. van Leeuwen, M. B. van't Veer, R. E. Curtis, et al. Second Cancers Among Long-Term Survivors of Hodgkin's Disease Diagnosed in Childhood and Adolescence J. Clin. Oncol., June 12, 2000; 18(12): 2435 - 2443. [Abstract] [Full Text] [PDF]

				D. M. Green, A. Hyland, M. P. Barcos, J. A. Reynolds, R. J. Lee, B. C. Hall, and M. A. Zevon Second Malignant Neoplasms After Treatment for Hodgkin’s Disease in Childhood or Adolescence J. Clin. Oncol., April 7, 2000; 18(7): 1492 - 1499. [Abstract] [Full Text] [PDF]

				R. T. Penson, M. V. Seiden, K. M. Shannon, M. L. Lubratovich, M. Roche, B. A. Chabner, and T. J. Lynch Jr. Communicating Genetic Risk: Pros, Cons, and Counsel Oncologist, April 1, 2000; 5(2): 152 - 161. [Abstract] [Full Text]

				F. E. van Leeuwen, W. J. Klokman, M. B. v.’t Veer, A. Hagenbeek, A. D. G. Krol, U. A. O. Vetter, M. Schaapveld, P. van Heerde, J. M. V. Burgers, R. Somers, et al. Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood J. Clin. Oncol., February 1, 2000; 18(3): 487 - 487. [Abstract] [Full Text] [PDF]

				K. E. Nichols, S. Levitz, K. E. Shannon, D. C.R. Wahrer, D. W. Bell, G. Chang, S. Hegde, D. Neuberg, T. Shafman, N. J. Tarbell, et al. Heterozygous Germline ATM Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease J. Clin. Oncol., April 1, 1999; 17(4): 1259 - 1259. [Abstract] [Full Text] [PDF]